Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Maj 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.2k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • BulderB Offline
    BulderB Offline
    Bulder
    wrote on sidst redigeret af
    #784

    asco abstracts are released at 23.00 tonight

    1 Reply Last reply
    0
    • G Offline
      G Offline
      GeorgeBest
      wrote on sidst redigeret af
      #785

      Thanks E L & Bulder

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #786

        good luck Helge, looking forward to the summaries tomorrow morning 😉

        1 Reply Last reply
        0
        • DarvinD Offline
          DarvinD Offline
          Darvin
          wrote on sidst redigeret af
          #787

          Rigth EL 17.10 65% increase compared to april 2020 and 46,5% increase compared to først 4 months 2020. Excellent

          1 Reply Last reply
          0
          • Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktørH Offline
            Helge_LarsenPI-redaktør
            wrote on sidst redigeret af
            #788

            E L I play football tonight with the young people in the club. Must therefore, as usual, go to bed early and get up late tomorrow. 😄

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #789

              a much better way to spend your time lol, enjoy!

              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #790

                Well, glofi har 3 pts ud af 52 med CRS grade 3. Epco har ingen over grade 2. Glofi: CRS was mostly(!) manageable.

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  peter12
                  wrote on sidst redigeret af
                  #791

                  Media release https://ir.genmab.com/news-releases/news-release-details/genmab-announces-abstracts-evaluating-products-pipeline

                  1 Reply Last reply
                  0
                  • BulderB Offline
                    BulderB Offline
                    Bulder
                    wrote on sidst redigeret af
                    #792

                    Responser synes jeg er svært at udlede, men epco nævner 55% CR og glofi nævner 57,1% CMR i dlbcl. Altså næsten det samme. Med alle forbehold.

                    1 Reply Last reply
                    0
                    • Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktørH Offline
                      Helge_LarsenPI-redaktør
                      wrote on sidst redigeret af
                      #793

                      Genmab vil præsentere data til kommende konferencer - GENT
                      https://www.proinvestor.com/investornyt/675234/genmab-vil-praesentere-data-til-kommende-konferencer-gent

                      1 Reply Last reply
                      0
                      • Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktørH Offline
                        Helge_LarsenPI-redaktør
                        wrote on sidst redigeret af
                        #794

                        God morgen. 🙂

                        1 Reply Last reply
                        0
                        • Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktørH Offline
                          Helge_LarsenPI-redaktør
                          wrote on sidst redigeret af
                          #795

                          Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be
                          Presented at American Society of Clinical Oncology : https://www.proinvestor.com/investornyt/675232/genmab-announces-abstracts-evaluating-products-in-pipeline-portfolio-to-be-presented-at-american-society-of-clinical-oncology

                          1 Reply Last reply
                          0
                          • Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktørH Offline
                            Helge_LarsenPI-redaktør
                            wrote on sidst redigeret af
                            #796

                            Torsdagens danske avisuddrag med Bitcoin, Salling Group og Rockwool: https://www.proinvestor.com/investornyt/675239/torsdagens-danske-avisuddrag-med-bitcoin-salling-group-og-rockwool

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #797

                              Er svagheden i biotekaktier forbigående?
                              Bryder Novo Nordisk ud af sit kursinterval? Er inflationsfaren reel – eller er det et buzzword? Samt verden ifølge elonmusk
                              & tsla. Lyt med i afsnit 66 af Investeringspodcasten med PerNordnet
                              ogHelgeLarsen. https://www.nordnet.dk/blog/afsnit-66-af-investeringspodcasten-om-biotekaktier-og-verden-ifoelge-elon-musk/
                              .

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #798

                                Bemærkningen “mostly manageable” er da interessant, som også bulder fremhæver 23:35

                                1 Reply Last reply
                                0
                                • JørgenVarnæsJ Offline
                                  JørgenVarnæsJ Offline
                                  JørgenVarnæs
                                  wrote on sidst redigeret af
                                  #799

                                  Bulder 13.56 tusind tak for info

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #800

                                    ASCO : Updated phase 1 results of teclistamab - https://meetinglibrary.asco.org/record/195433/abstract

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #801

                                      ASCO : Updated results of a phase 1, first-in-human study of talquetamab - https://meetinglibrary.asco.org/record/195432/abstract

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #802

                                        I didn't realise JNJ are also trying Amivantamab subcutaneous WITHOUT hyaluronidase , so just SC administration of a low concentration (50 mg/mL) formulation of amivantamab alone. Let's hope that works well enough. https://meetinglibrary.asco.org/record/201164/abstract

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #803

                                          any thoughts on Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed? https://meetinglibrary.asco.org/record/196820/abstract
                                          not sure if this is the same sub-group as previously presented?

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger